Catalog No.
Product Name
Application
Product Information
Citations
-
H+/K+-ATPase Inhibitor
(R)-Tegoprazan is a potent H+/K+-ATPase inhibitor characterized by its benzimidazole structure. It demonstrates an IC50 of 98 nM against canine kidney Na+/K+-ATPase, highlighting its efficacy in modulating ion transport. This compound is prominently applied in research related to gastrointestinal diseases, offering valuable insights into therapeutic interventions. -
Proton Pump Inhibitor
Zastaprazan is a potent proton pump inhibitor that functions as a potassium-competitive acid blocker. It is utilized in research related to gastrointestinal inflammatory diseases and gastric acid-related conditions, including gastroesophageal reflux disease. This compound provides valuable insights into mechanisms of acid secretion and potential therapeutic approaches in the treatment of acid-related disorders. -
Stable Isotope
Abscisic acid-d6 is a deuterium-labeled derivative of abscisic acid, functioning as a stable isotope. This compound is known for its ability to inhibit the proton pump (H+-ATPase), making it a valuable tool for investigating physiological processes regulated by abscisic acid. Its applications extend to studying plant stress responses, signal transduction pathways, and metabolic regulation in various biological systems. -
Proton-pump Inhibitor
5-Hydroxylansoprazole is a metabolite of Lansoprazole, acting as a proton-pump inhibitor. This compound is instrumental in reducing gastric acid secretion, thereby aiding in the treatment of various peptic disorders. Its primary application in research includes the investigation of acid-related gastrointestinal conditions and the pharmacokinetics of proton-pump inhibitors. -
Proton Pump Inhibitor
Padoprazanum is a proton pump inhibitor that works by irreversibly blocking the H+/K+ ATPase enzyme in the gastric parietal cells. This inhibition effectively reduces gastric acid secretion, making it useful in the treatment of various acid-related gastrointestinal disorders. Key research applications include the investigation of acid secretion mechanisms and the study of therapeutic strategies for conditions such as gastroesophageal reflux disease (GERD) and peptic ulcers. -
PM H+-ATPase Inhibitor
Protonstatin-1 is a selective inhibitor of the plasma membrane H+-ATPase, exhibiting an IC50 of 3.9 μM. By interacting with the central loop of the enzyme, Protonstatin-1 disrupts the functions of the N- and P-domains, ultimately inhibiting pump activity and auxin transport. This reagent is valuable for research in plant physiology and studies involving cellular ion homeostasis. -
V-ATPase Inhibitor
V-ATPase-IN-1 is a selective inhibitor of Vacuolar-type H+-ATPases (V-ATPase), demonstrating an IC50 value of 194.80 μM and a binding affinity for the V-ATPase subunit A with a Kd of 0.803 μM. This compound exhibits notable insecticidal activity against M. separata, with an LC50 of 2.64 mM. V-ATPase-IN-1 is a valuable tool in research focused on the development of chemical insecticides and understanding the biological role of V-ATPase in various organisms. -
H+-K+-ATPase Inhibitor
(±)-Vasicine is a potent inhibitor of H+-K+-ATPase, with an observed IC50 of 73.47 μg/mL. This compound exhibits notable anti-ulcer properties, demonstrating significant anti-secretory, antioxidant, and cytoprotective effects. As such, (±)-Vasicine serves as a valuable reagent for research applications focused on gastrointestinal protection and related mechanisms in cellular physiology. -
H(+), K(+)-ATPase Inhibitor
Lansoprazole sulfone is a selective inhibitor of H+, K+-ATPase, primarily targeting gastric acid secretion. By inhibiting this enzyme, lansoprazole sulfone may significantly stimulate gastric acid secretion, making it a valuable tool in research related to gastric physiology. Its potential applications extend to the study of conditions such as duodenal ulcers, gastric ulcers, gastroesophageal reflux disease, and Zollinger-Ellison syndrome. -
RUVBL1/2 ATPase Inhibitor
TIP48/49-IN-1 is a selective inhibitor of the RUVBL1/2 ATPase, demonstrating an IC50 of 59 nM against purified RUVBL1/2. By disrupting the DNA replication process, TIP48/49-IN-1 induces S-phase arrest and apoptosis in cancer cells. This compound has been shown to inhibit tumor growth and enhance radiosensitivity in non-small cell lung cancer (NSCLC) models, making it a valuable tool for cancer research. -
Proton Pump Inhibitor
Padoprazanum hydrochloride is a proton pump inhibitor that selectively targets gastric proton pumps, reducing acid secretion in the stomach. This compound demonstrates significant efficacy in the treatment of acid-related disorders such as gastroesophageal reflux disease (GERD) and peptic ulcers. Its unique mechanism of action makes it a valuable tool for researchers studying gastric secretion and related gastrointestinal conditions. -
Proton Pump Inhibitor
Omeprazole magnesium is an orally active proton pump inhibitor (PPI) that effectively suppresses gastric acid secretion. It is utilized in research related to acid reflux symptoms and frequent heartburn, making it a valuable tool for investigating gastrointestinal disorders and related therapeutic interventions. -
Proton Pump Inhibitor
Linaprazan mesylate is a proton pump inhibitor that targets the H+,K+ -ATPase enzyme in the gastric mucosa through competitive binding with potassium ions. With an IC50 value of 1.0 ± 0.2 μM, it exhibits potent inhibitory effects on gastric acid secretion. This compound is particularly applicable in studies related to gastroesophageal reflux disease and reflux esophagitis, facilitating research on its therapeutic potential. -
Stable Isotope
Esomeprazole-d6 sodium is a deuterium-labeled derivative of Esomeprazole. This compound functions primarily as a proton pump inhibitor, effectively reducing gastric acid secretion by inhibiting the H+, K+-ATPase enzyme in gastric parietal cells. Esomeprazole-d6 sodium is valuable for research applications focused on gastroesophageal reflux disease, enabling the study of metabolic pathways and pharmacokinetics in related therapeutic investigations. -
H+, K+-ATPase Inhibitor
S 1924 is a potent H+, K+-ATPase inhibitor, demonstrating IC50 values of 10.3 μM at pH 7.4 and 1.6 μM at pH 6.0. This compound effectively modulates gastric acid secretion, making it valuable in research related to gastrointestinal physiology and pharmacology. Its specificity for H+, K+-ATPase makes S 1924 a useful tool for investigating proton pump mechanisms and related therapeutic targets. -
Proton Pump Inhibitor
AGN-201904Z is a novel proton pump inhibitor that effectively inhibits gastric acid secretion. This compound demonstrates enhanced and sustained acid suppression effects compared to traditional agents such as esomeprazole. AGN-201904Z is valuable for research applications aimed at studying gastric disorders and evaluating the physiological impacts of prolonged acid suppression. -
Proton Pump Inhibitor
Saviprazole is a proton pump inhibitor that effectively reduces gastric acid secretion by irreversibly inhibiting the H+/K+ ATPase enzyme in gastric parietal cells. This compound demonstrates significant biological activity in the treatment of gastrointestinal diseases, particularly in conditions such as gastric ulcers and acid reflux. Its application in research provides valuable insights into acid-related disorders and potential therapeutic interventions. -
Proton Pump Inhibitor
Tiludronate, a bisphosphonate with proton pump inhibitor activity, primarily targets the osteoclast vacuolar H(+)-ATPase to regulate bone metabolism. It exhibits potent antiresorptive and anti-inflammatory properties, making it valuable for studying metabolic bone disorders. Its role in inhibiting osteoclast function positions Tiludronate as a critical tool for research focused on bone health and related diseases. -
Proton Pump Inhibitor
Padoprazanum fumarate is a proton pump inhibitor that targets the H+/K+ ATPase enzyme in gastric parietal cells, effectively reducing gastric acid secretion. It demonstrates notable efficacy in the treatment of conditions such as gastroesophageal reflux disease (GERD) and peptic ulcers. This compound serves as a valuable tool for researchers investigating gastric acid regulation and related gastrointestinal disorders. -
V ATPase Inhibitor
FR-167356 is a selective inhibitor of vacuolar ATPase, exhibiting potent activity with IC50 values of 170 nM for osteoclast plasma membranes, 220 nM for macrophage microsomes, and higher values for renal brush border and liver lysosomal membranes. This compound inhibits bone resorption and effectively addresses ovariectomy-induced bone loss. It serves as a valuable tool for research into osteoporosis and related bone disorders. -
Proton Pump Inhibitor
WY-47766 is a potent proton pump inhibitor that targets the gastric H+/K+ ATPase enzyme. Its primary mechanism involves the irreversible binding to the enzyme, leading to a significant reduction in gastric acid secretion. WY-47766 is utilized in research applications focused on understanding gastric physiology, acid secretion disorders, and the development of therapeutic strategies for related gastrointestinal diseases. -
Proton Pump Inhibitor
(R)-(+)-Pantoprazole sodium is a potent proton pump inhibitor that selectively targets the H+/K+ ATPase enzyme in gastric parietal cells. This compound is primarily utilized in research related to gastroesophageal reflux disease, aiding in the elucidation of gastric acid secretion mechanisms and therapies. Its ability to effectively reduce gastric acidity makes it a valuable tool for studying acid-related disorders and developing therapeutic strategies. -
V-ATPase Inhibitor
Apicularen B is a potent V-ATPase inhibitor derived from the myxobacterium Archangium gephyra. This cytotoxic macrolide exhibits significant biological activity relevant to the study of V-ATPase-related disorders, including osteopetrosis. Researchers can utilize Apicularen B to investigate the mechanisms underlying these diseases and explore potential therapeutic applications. -
proton pump Inhibitor
AGN-201904 is a proton pump inhibitor that functions as an omeprazole prodrug. This compound has shown potential in delaying aging processes and is effective in the prevention and inhibition of peptic ulcers. Its biological activity makes it a valuable tool in research focused on gastrointestinal health and the mechanisms of aging. -
H+/K+-ATPase Inhibitor
KR-60436 is a reversible inhibitor of H+/K+-ATPase, effectively obstructing proton and potassium transport across cellular membranes. This compound has demonstrated potent inhibition of CYP1A2 substrate metabolism, making it a valuable tool for studying gastric proton pump activity and its implications in drug metabolism. Its utility extends to drug interaction studies and the investigation of gastrointestinal pharmacology. -
Proton Pump Inhibitor
SKF96067 is a reversible inhibitor of the gastric H+/K+-ATPase, primarily targeting proton pumps involved in gastric acid secretion. This compound demonstrates significant biological activity in reducing gastric acid production, making it useful in research related to gastrointestinal diseases and acid-related disorders. Its modulation of proton pump activity aids in elucidating mechanisms of acid secretion regulation and the potential therapeutic effects on related pathologies. -
Cinnamic Acid Derivative
2-(Trifluoromethyl)cinnamic acid is a cinnamic acid derivative that acts as an inhibitor of the proton pump (H+/K+-ATPase), leading to a reduction in gastric acid secretion. This compound has demonstrated biological activity in improving delayed gastric emptying and is valuable for research on gastric pathologies, including acute gastritis and gastric ulcers. Its unique properties make it an important reagent for studies investigating gastric health and related disorders. -
Proton Pump Inhibitor
Nepaprazole is a proton pump inhibitor that targets H+/K+-ATPase activity, significantly reducing gastric acid secretion. It demonstrates inhibitory effects in isolated rabbit gastric mucosal microsomes with IC50 values of 5.8 μM and 9.9 μM at pH 6.0 and pH 7.4, respectively. This compound is primarily utilized in research related to peptic ulcer diseases, providing insights into gastric acid regulation and potential therapeutic interventions. -
Proton Pump Inhibitor
Tenatoprazole sodium is a potent proton pump inhibitor that specifically targets the hog gastric H+/K+-ATPase, exhibiting an IC50 of 6.2 μM. This compound effectively decreases gastric acid secretion, making it valuable for research in gastrointestinal disorders and related therapeutic applications. Its mechanism of action positions it as a useful tool for studying the regulation of gastric acidity and the underlying pathways involved in acid-related diseases. -
Proton Pump Inhibitor
S3337 is a potent inhibitor of H+, K+-ATPase, a key enzyme responsible for regulating gastric acid secretion. By targeting this proton pump, S3337 effectively reduces gastric acid production, making it valuable for research into acid-related disorders. Its primary applications include studies on gastritis, peptic ulcers, and gastroesophageal reflux disease (GERD). -
SGLT2 Inhibitor
WAY-123783 is a selective and orally active sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor. It effectively enhances urinary glucose excretion while simultaneously lowering blood glucose levels in db/db mice, with an ED50 of 9.85 mg/kg. This compound is valuable for research in metabolic diseases, particularly diabetes, facilitating studies on glucose regulation and potential therapeutic interventions. -
SGLT2 Inhibitor
SGLT2-IN-1 is a selective inhibitor of the sodium-dependent glucose cotransporter SGLT2, exhibiting an IC50 of 33 nM in CHO cells transfected with human SGLT2. This compound demonstrates selectivity for SGLT2 over SGLT1, making it a valuable tool for research in glucose homeostasis and metabolic disorders. Additionally, SGLT2-IN-1 serves as an active metabolite of dapagliflozin, contributing to studies focused on diabetes and its associated complications. -
SGLT2 Inhibitor
Henagliflozin is a selective sodium-glucose co-transporter 2 (SGLT2) inhibitor with an IC50 value of 2.38 nM for human SGLT2, exhibiting minimal activity against SGLT1 with an IC50 of 4324 nM. This compound is instrumental in diabetes research, facilitating studies on glucose homeostasis and potential therapeutic strategies for diabetic conditions. Its high selectivity and potency make it a valuable tool for investigating the physiological and pharmacological roles of SGLT2 in metabolic disorders. -
Stable Isotope
Empagliflozin-d4 is a deuterium-labeled derivative of Empagliflozin, a selective sodium-glucose cotransporter-2 (SGLT-2) inhibitor. With an IC50 of 3.1 nM for human SGLT-2, this stable isotope is utilized primarily in pharmacokinetic studies and metabolic research. Its labeling facilitates the investigation of drug metabolism and the tracking of pharmacological effects in biological systems. -
SGLT-2 Inhibitor
Enavogliflozin is a highly selective sodium-glucose cotransporter-2 (SGLT-2) inhibitor that exhibits potent antidiabetic activity. By inhibiting SGLT-2, Enavogliflozin reduces glucose reabsorption in the kidneys, promoting increased glucose excretion in urine and thereby lowering blood glucose levels. This compound is primarily employed in research applications focused on diabetes management and cardiovascular health. -
SGLT-2 Inhibitor
Tianagliflozin is a selective inhibitor of sodium/glucose cotransporter 2 (SGLT-2), offering potential therapeutic benefit in the management of type 2 diabetes mellitus. By inhibiting SGLT-2, Tianagliflozin promotes the excretion of glucose through the kidneys, thereby lowering blood glucose levels. This compound is of interest in research focused on innovative treatments for glycemic control and metabolic regulation in diabetic patients. -
SGLT2 Inhibitor
Remogliflozin etabonate is a selective inhibitor of the sodium glucose cotransporter 2 (SGLT2), exhibiting Ki values of 1.95 μM for human SGLT2, 2.14 μM for rat SGLT2, 43.1 μM for human SGLT1, and 8.57 μM for rat SGLT1. As a prodrug derived from benzylpyrazole glucoside, it is metabolized into its active form, Remogliflozin, in vivo. This compound demonstrates significant antidiabetic activity in rodent models, making it a valuable tool for research into glucose regulation and diabetes therapies. -
Stable Isotope
Dapagliflozin-d5 is a deuterated form of Dapagliflozin, a selective inhibitor of the sodium-glucose cotransporter 2 (SGLT2). This stable isotope is utilized in metabolic studies and pharmacokinetic research to trace the absorption and distribution of Dapagliflozin in biological systems. Its application in advanced research provides insights into the drug's mechanism and efficacy in managing diabetes. -
Stable Isotope
Canagliflozin-d4 is a deuterium-labeled derivative of Canagliflozin, a selective inhibitor of the sodium-glucose cotransporter 2 (SGLT2). This stable isotope is primarily utilized in pharmacokinetic studies and metabolic research to trace and quantify the pharmacological fate of Canagliflozin in biological systems. The presence of deuterium allows for enhanced detection and analysis, facilitating investigations into glucose homeostasis and associated therapeutic applications in diabetes management. -
SGLT2 Inhibitor
Sergliflozin etabonate is a potent and orally active sodium-glucose cotransporter 2 (SGLT2) inhibitor. It exhibits significant antidiabetic and antihyperglycemic effects, as evidenced by its ability to markedly reduce non-fasting blood glucose levels in diabetic mouse models. This compound is primarily utilized in diabetes research to explore therapeutic strategies for glucose management and metabolic regulation. -
SGLT1/SGLT2 Inhibitor
SGLT1/2-IN-1 is a dual inhibitor of SGLT1 and SGLT2, designed to effectively modulate glucose transport mechanisms. This compound exhibits significant biological activity in reducing glucose reabsorption in the kidneys and intestines, making it a valuable tool for research in diabetes and metabolic disorders. Its applications extend to investigating the role of sodium-glucose transporters in glucose homeostasis and potential therapeutic interventions for hyperglycemia. -
SGLT2 Inhibitor
Luseogliflozin hydrate is a selective and potent second-generation sodium-glucose co-transporter 2 (SGLT2) inhibitor, exhibiting an IC50 value of 2.26 nM. This compound is primarily utilized in research focused on type 2 diabetes mellitus (T2DM), where its ability to inhibit SGLT2 facilitates the reduction of glucose reabsorption in the kidneys, thereby lowering blood glucose levels. -
SGLT-2 Inhibitor
Rongliflozin is a selective and orally active inhibitor of sodium-glucose co-transporter-2 (SGLT-2), which plays a crucial role in glucose reabsorption in the kidneys. This compound exhibits significant biological activity in the regulation of glucose metabolism and has potential applications in the treatment of type 2 diabetes mellitus (T2DM). Research with Rongliflozin can further elucidate its therapeutic effects and mechanisms of action in managing glycemic control. -
SGLT Inhibitor
rel-Licogliflozin is a sodium glucose cotransporter (SGLT) inhibitor, specifically targeting SGLT1 and SGLT2. This compound demonstrates significant biological activity in glucose transport modulation, making it valuable for research into diabetes and other metabolic disorders. Its role in disrupting glucose reabsorption in the kidneys has potential applications in developing therapeutic strategies for hyperglycemia management. -
SGLT-2 Inhibitor
Atigliflozin is a selective sodium-glucose cotransporter 2 (SGLT-2) inhibitor, displaying IC50 values of 10 nM for hSGLT-2 and 8.2 μM for hSGLT-1. This compound is effective in lowering blood glucose levels and enhancing impaired oral glucose tolerance. Atigliflozin is utilized in research related to type II diabetes mellitus, contributing to the understanding of glucose regulation and potential therapeutic interventions. -
SGLT Inhibitor
Velagliflozin proline is an oral sodium-glucose cotransporter 2 (SGLT2) inhibitor that exhibits significant antidiabetic activity. This compound effectively reduces renal glucose reabsorption, leading to increased glycosuria, which in turn lowers blood glucose and insulin levels. Velagliflozin proline is primarily utilized in research focused on diabetes management and related metabolic disorders. -
SGLT Inhibitor
SGLT1/2-IN-2 is a potent dual inhibitor targeting sodium-glucose co-transporters 1 and 2 (SGLT1 and SGLT2), with IC50 values of 96 nM and 1.3 nM, respectively. This compound effectively regulates glucose absorption and reabsorption in the kidneys, making it a valuable tool in diabetes research. Its dual inhibitory action offers significant potential in studying glucose homeostasis and developing therapies for metabolic disorders. -
SGLT1/2 Inhibitor
SGLT1/2-IN-8 is a potent dual inhibitor of SGLT1 and SGLT2, exhibiting IC50 values of 4 nM and 1 nM, respectively. This compound demonstrates significant anti-hyperglycemic effects, making it a valuable tool for research in diabetes and glucose regulation. Its oral bioavailability supports its potential in in vivo studies aimed at exploring metabolic disorders. -
Stable Isotope
Empagliflozin-d8 is a deuterium-labeled derivative of Empagliflozin, a selective sodium-glucose cotransporter-2 (SGLT-2) inhibitor. With an IC50 of 3.1 nM for human SGLT-2, this compound exhibits significant biological activity in glucose regulation and is utilized in diabetes research. Its stable isotope labeling enables enhanced analytical sensitivity and specificity in pharmacokinetic studies and metabolic profiling. -
SGLT2 Inhibitor
BI-44847 is a selective and orally active inhibitor of the sodium-glucose cotransporter 2 (SGLT2), primarily targeting glucose reabsorption in the kidneys. This compound is known to enhance urinary glucose excretion (UGE) and reduce HbA1c levels, thus improving both fasting and postprandial glucose levels. BI-44847 is valuable for research applications focused on understanding and treating type 2 diabetes mellitus (T2DM).
